Literature DB >> 29089644

Prognostic significance of ASXL1 mutation types and allele burden in myelofibrosis.

A Tefferi1, T L Lasho1, C Finke1, N Gangat1, C A Hanson2, R P Ketterling3, A Pardanani1.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2017        PMID： 29089644     DOI： 10.1038/leu.2017.318

Source DB:  PubMed          Journal:  Leukemia        ISSN： 0887-6924            Impact factor:   11.528


× No keyword cloud information.
  15 in total

1.  Prognostic significance of ASXL1 mutations in patients with myelodysplastic syndromes.

Authors:  Felicitas Thol; Inna Friesen; Frederik Damm; Haiyang Yun; Eva M Weissinger; Jürgen Krauter; Katharina Wagner; Anuhar Chaturvedi; Amit Sharma; Martin Wichmann; Gudrun Göhring; Christiane Schumann; Gesine Bug; Oliver Ottmann; Wolf-Karsten Hofmann; Brigitte Schlegelberger; Michael Heuser; Arnold Ganser
Journal:  J Clin Oncol       Date:  2011-05-16       Impact factor: 44.544

2.  Acquired mutations in ASXL1 in acute myeloid leukemia: prevalence and prognostic value.

Authors:  Marta Pratcorona; Saman Abbas; Mathijs A Sanders; Jasper E Koenders; François G Kavelaars; Claudia A J Erpelinck-Verschueren; Annelieke Zeilemakers; Bob Löwenberg; Peter J M Valk
Journal:  Haematologica       Date:  2011-11-04       Impact factor: 9.941

3.  ASXL1 mutations are frequent and prognostically detrimental in CSF3R-mutated chronic neutrophilic leukemia.

Authors:  Michelle A Elliott; Animesh Pardanani; Curtis A Hanson; Terra L Lasho; Christy M Finke; Alem A Belachew; Ayalew Tefferi
Journal:  Am J Hematol       Date:  2015-07       Impact factor: 10.047

4.  Targeted deep sequencing in primary myelofibrosis.

Authors:  Ayalew Tefferi; Terra L Lasho; Christy M Finke; Yoseph Elala; Curtis A Hanson; Rhett P Ketterling; Naseema Gangat; Animesh Pardanani
Journal:  Blood Adv       Date:  2016-11-30

5.  Clinical effect of point mutations in myelodysplastic syndromes.

Authors:  Rafael Bejar; Kristen Stevenson; Omar Abdel-Wahab; Naomi Galili; Björn Nilsson; Guillermo Garcia-Manero; Hagop Kantarjian; Azra Raza; Ross L Levine; Donna Neuberg; Benjamin L Ebert
Journal:  N Engl J Med       Date:  2011-06-30       Impact factor: 91.245

6.  New prognostic scoring system for primary myelofibrosis based on a study of the International Working Group for Myelofibrosis Research and Treatment.

Authors:  Francisco Cervantes; Brigitte Dupriez; Arturo Pereira; Francesco Passamonti; John T Reilly; Enrica Morra; Alessandro M Vannucchi; Ruben A Mesa; Jean-Loup Demory; Giovanni Barosi; Elisa Rumi; Ayalew Tefferi
Journal:  Blood       Date:  2008-11-06       Impact factor: 22.113

7.  Mutations and prognosis in primary myelofibrosis.

Authors:  A M Vannucchi; T L Lasho; P Guglielmelli; F Biamonte; A Pardanani; A Pereira; C Finke; J Score; N Gangat; C Mannarelli; R P Ketterling; G Rotunno; R A Knudson; M C Susini; R R Laborde; A Spolverini; A Pancrazzi; L Pieri; R Manfredini; E Tagliafico; R Zini; A Jones; K Zoi; A Reiter; A Duncombe; D Pietra; E Rumi; F Cervantes; G Barosi; M Cazzola; N C P Cross; A Tefferi
Journal:  Leukemia       Date:  2013-04-26       Impact factor: 11.528

Review 8.  The 2016 revision to the World Health Organization classification of myeloid neoplasms and acute leukemia.

Authors:  Daniel A Arber; Attilio Orazi; Robert Hasserjian; Jürgen Thiele; Michael J Borowitz; Michelle M Le Beau; Clara D Bloomfield; Mario Cazzola; James W Vardiman
Journal:  Blood       Date:  2016-04-11       Impact factor: 22.113

9.  ASXL1 mutations promote myeloid transformation through loss of PRC2-mediated gene repression.

Authors:  Omar Abdel-Wahab; Mazhar Adli; Lindsay M LaFave; Jie Gao; Todd Hricik; Alan H Shih; Suveg Pandey; Jay P Patel; Young Rock Chung; Richard Koche; Fabiana Perna; Xinyang Zhao; Jordan E Taylor; Christopher Y Park; Martin Carroll; Ari Melnick; Stephen D Nimer; Jacob D Jaffe; Iannis Aifantis; Bradley E Bernstein; Ross L Levine
Journal:  Cancer Cell       Date:  2012-08-14       Impact factor: 31.743

10.  SETBP1 mutations drive leukemic transformation in ASXL1-mutated MDS.

Authors:  D Inoue; J Kitaura; H Matsui; H-A Hou; W-C Chou; A Nagamachi; K C Kawabata; K Togami; R Nagase; S Horikawa; M Saika; J-B Micol; Y Hayashi; Y Harada; H Harada; T Inaba; H-F Tien; O Abdel-Wahab; T Kitamura
Journal:  Leukemia       Date:  2014-10-13       Impact factor: 11.528
View more
  8 in total

Review 1.  JAK2 (and other genes) be nimble with MPN diagnosis, prognosis, and therapy.

Authors:  Michele Ciboddo; Ann Mullally
Journal:  Hematology Am Soc Hematol Educ Program       Date:  2018-11-30

2.  Genomic analysis of primary and secondary myelofibrosis redefines the prognostic impact of ASXL1 mutations: a FIM study.

Authors:  Damien Luque Paz; Jérémie Riou; Emmanuelle Verger; Bruno Cassinat; Aurélie Chauveau; Jean-Christophe Ianotto; Brigitte Dupriez; Françoise Boyer; Maxime Renard; Olivier Mansier; Anne Murati; Jérôme Rey; Gabriel Etienne; Véronique Mansat-De Mas; Suzanne Tavitian; Olivier Nibourel; Stéphane Girault; Yannick Le Bris; François Girodon; Dana Ranta; Jean-Claude Chomel; Pascale Cony-Makhoul; Pierre Sujobert; Margot Robles; Raouf Ben Abdelali; Olivier Kosmider; Laurane Cottin; Lydia Roy; Ivan Sloma; Fabienne Vacheret; Mathieu Wemeau; Pascal Mossuz; Borhane Slama; Vincent Cussac; Guillaume Denis; Anouk Walter-Petrich; Barbara Burroni; Nathalie Jézéquel; Stéphane Giraudier; Eric Lippert; Gérard Socié; Jean-Jacques Kiladjian; Valérie Ugo
Journal:  Blood Adv       Date:  2021-03-09

3.  U2AF1 mutation types in primary myelofibrosis: phenotypic and prognostic distinctions.

Authors:  Ayalew Tefferi; Christy M Finke; Terra L Lasho; Curtis A Hanson; Rhett P Ketterling; Naseema Gangat; Animesh Pardanani
Journal:  Leukemia       Date:  2018-02-27       Impact factor: 11.528

4.  State-of-the-art review: allogeneic stem cell transplantation for myelofibrosis in 2019.

Authors:  Donal P McLornan; Ibrahim Yakoub-Agha; Marie Robin; Yves Chalandon; Claire N Harrison; Nicolaus Kroger
Journal:  Haematologica       Date:  2019-03-14       Impact factor: 9.941

5.  Prognostic value of ASXL1 mutations in patients with primary myelofibrosis and its relationship with clinical features: a meta-analysis.

Authors:  Ziqing Wang; Weiyi Liu; Mingjing Wang; Yujin Li; Xueying Wang; Erpeng Yang; Jing Ming; Richeng Quan; Xiaomei Hu
Journal:  Ann Hematol       Date:  2021-01-02       Impact factor: 3.673

Review 6.  Clonal Hematopoiesis and Mutations of Myeloproliferative Neoplasms.

Authors:  Lasse Kjær
Journal:  Cancers (Basel)       Date:  2020-07-28       Impact factor: 6.639

Review 7.  Next Generation Sequencing in MPNs. Lessons from the Past and Prospects for Use as Predictors of Prognosis and Treatment Responses.

Authors:  Vibe Skov
Journal:  Cancers (Basel)       Date:  2020-08-06       Impact factor: 6.639

Review 8.  The Molecular Genetics of Myeloproliferative Neoplasms.

Authors:  Anna E Marneth; Ann Mullally
Journal:  Cold Spring Harb Perspect Med       Date:  2020-02-03       Impact factor: 6.915
  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.